HTLZF yields 125.78% · JNJ yields 2.13%● Live data
📍 HTLZF pulled ahead of the other in Year 1
Combined, HTLZF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HTLZF + JNJ for your $10,000?
Hamilton Thorne Ltd. develops, manufactures, and sells precision instruments, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets. It offers precision laser systems, imaging systems, and other equipment and consumables for the ART and developmental biology research markets under the Hamilton Thorne brand; test laboratory and endotoxin testing services, as well as sperm assays, including Sperm Motility Index and Sperm Penetration; and fresh and cryopreserved mouse embryos supply, and technician training and proficiency testing services under the Embryotech brand. The company also manufactures and distributes products for reproductive medicine, including clinical and laboratory equipment and disposables, as well as complete installations of ART clinics under the Gynemed brand; and bench top incubators, programmable freezers, loggers, alarms, cryo storage, and software systems and sensors for the safe preservation of medical and biological specimens used in ART and cell biology applications under the Planer brand. It sells its products and services through a direct sales force in the United States, Germany, France, and the United Kingdom, as well as through distributors to approximately 2,000 fertility clinics, hospitals, pharmaceutical companies, biotechnology companies, educational institutions, and other commercial and academic research establishments in approximately 75 countries. The company is headquartered in Beverly, Massachusetts.
Full HTLZF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.